Louis Fourie
ALTHOUGH the pharmaceutical industry is constantly evolving and new therapeutic approaches are being developed, one aspect has not changed: the use of small, synthetic molecules, which still account for 90 percent of the therapeutics on the pharmaceutical market. Some of the top-selling drugs are small-molecule drugs.
Small-molecule drugs
A small-molecule drug is an organic compound of low molecular weight (less than 900 Daltons or 1,49449-21 grams) and the size of about one nanometre capable of modulating biochemical processes to diagnose, treat or prevent diseases.
Because of their low molecular weight, small-molecule drugs have some definite advantages as therapeutics, because most can be administered orally and can pass through cell membranes to reach intracellular targets. Once inside the cells, they can be designed to engage biological targets, such as proteins, by various modes of action. Their distribution can also be customised, for example, to allow for systemic exposure or to destroy cancer cells. Therefore, many targeted therapies today are small-molecule drugs made from synthetic chemical reactions. However, they are also used in pesticides and in many other roles.
One well-known small-molecule drug is aspirin, which has been with us since 1899. Currently, the world consumes about 40000 tons of aspirin every year for a range of indications, such as cardiovascular health, Alzheimers disease, cancer treatment, pulmonary diseases, and everyday aches and pains. Another classic example is the drug penicillin, which successfully reduced the death rate caused by bacterial-related pneumonia to less than 1 percent during World War II.
Although small-molecule drugs have dominated the pharmaceutical industry since the beginning of modern medicine, it seems as though major developments are now happening in biologics, despite their excessive cost. RNA interference and CRISPR-Cas9, for example, are exciting new gene-editing tools.
But it is not the end of small-molecule medicine. Recent discoveries of small molecules that can modulate protein-protein interactions have created renewed interest in and utilities for small-molecule drugs for many diseases.Furthermore, the ability to design small molecules that can interact with and modulate RNA could create new opportunities for targeting challenging disease pathways.
An anti-ageing drug
Although with us for many years, the rapid advancement of biopharmaceutical research and technology opens up many opportunities for inventive and ingenious approaches to developing small-molecule drugs. We have therefore in recent years seen that significant advancements in structure-based design and imaging, together with automation, artificial intelligence and machine learning, have become important enablers to expedite research and enhance the success rate of small-molecule-led optimisation.
One of these innovative small-molecule drugs that could delay ageing is being tested by the US Militarys Special Operations Command (Socom), the organisation that controls the USs Special Operations forces. The anti-ageing pill comprises a human performance small molecule in the form of a nutraceutical with the aim of improving performance characteristics such as endurance and faster recovery from injuries, which typically declines with age.
Socom is working with the private biotech laboratory Metro International Biotech (MetroBiotech) on the development of an anti-ageing pill based on a human performance small molecule.
MetroBiotech is an offshoot of David Sinclairs Harvard University Medical School laboratory. The first-in-class small molecule on which they are working is Nicotinamide Mononucleotide (NMN), which MetroBiotech describes on their website as an enhancer that leverages the nicotinamide adenine dinucleotide (NAD+) cycle that is critically important to the function of all living cells and also to treat rare mitochondrial diseases and other medical conditions. These rare mitochondrial diseases often have serious effects on skeletal and cardiac muscle, as well as the central nervous system.
Increased NAD+ levels have been shown to induce mitochondrial biogenesis and enhance natural pathways (for example, sirtuins a family of dormant proteins found in all living beings) that are key to improving mitochondrial health. Mitochondria are cell parts (organelles) that produce energy for the cell in the form of a chemical called adenosine triphosphate (ATP). Cells need ATP to function properly, and NAD+ is a cofactor required for the enzymatic processes that generate energy within the cell through the continuous production of ATP inside the mitochondria.
Research has demonstrated the broad therapeutic potential of increasing NAD+ levels to preserve health and normal metabolism. It increases mitochondrial health and longevity, rejuvenates stem cells and provides neuroprotection. In general, it improves the health of most organs such as the brain (neurodegeneration), heart (inflammation, cardio protection), liver fatty acid oxidation, gluconeogenesis or regeneration), pancreas (insulin secretion), and skeletal muscles (insulin sensitivity, fatty acid oxidation) and white adipose tissue or white fat (lipogenesis).
Ageing and certain diseases, such as mitochondrial dysfunction, inflammation and other associated diseases, cause a decline in the NAD+ levels in humans, with serious consequences with regard to energy, performance and endurance. Treating people with NAD+ could thus slow the degenerative effects of ageing, prevent the onset of injury and thus allow people, according to MetroBiotech, to lead longer and healthier lives.
Several studies have been published in respected journals indicating how supplementation with a NAD precursor delays motor neuron degeneration, decreases markers of neuroinflammation in the spinal cord, improves blood flow, heart pathology, and musculoskeletal endurance, slows Alzheimers, improves energy metabolism, insulin sensitivity and plasma lipid profile, reverses retinal degeneration, mitochondrial biogenesis in skeletal muscle, and prevents noise-induced hearing loss and spiral ganglion neuron degeneration after noise exposure.
Since the small-molecule drug is a nutraceutical, a dietary supplement or food containing health-giving additive with medicinal benefit, it is not regulated by the US Food and Drug Administration and is therefore exempt from the rigorous standards regulating prescription drugs. It seems that MetroBiotech is following the nutraceutical route and not that of a prescription drug, because ageing is not yet itself a diagnosable disease to be treated by a prescription. Still, Socom have finished pre-clinical safety and dosing studies, and will soon start performance testing of the anti-ageing pill in clinical trials.
The thinking behind the anti-ageing pill is to address the cause of mitochondrial diseases and cure them all at once instead of the current repetitious and often futile one-by-one approach. According to MetroBiotech, its technology also supports key organ functions and could slow neurodegeneration, decrease inflammation in the body, increase cardio protection and improve sleep. NAD+ can apparently also reduce the functional effects of ageing on the human body, such as speed and reaction time.
A pipedream or a breakthrough?
For as long as humans have existed, they have been on a quest for a magic substance that would extend life or even bestow immortality. Over the years, the medieval alchemists and many others pursued the elixir of life. The slowing or prevention of ageing has therefore long been the Holy Grail of medicine, but has largely evaded us until now, except for a few studies in their infancy, such as Israeli oxygen therapy to increase telomere length and decrease the number of senescent cells (geriatric cells that can no longer divide).
The anti-ageing pill of MetroBiotech that slows down ageing and keeps you young may therefore sound like a sci-fi story. We will thus have to wait for the clinical trials to prove that NAD+ can indeed do what MetroBiotech is claiming it can do. However, the US military has spent serious money on this nutraceutical about R41 million since 2018. It must thus indeed be a promising drug that could become a game-changer in slowing the effects of ageing and preventing the onset of injuries. Despite being a controversial figure and often criticised, Sinclair may indeed be on the verge of a public health breakthrough that we have never seen before.
See you at our 150-year party!
Professor Louis CH Fourie is a technology strategist.
*The views expressed here are not necessarily those of IOL or of title sites.
BUSINESS REPORT ONLINE
Continued here:
Tech news: Soon you will be able to stay young forever By Louis Fourie Jul 19 - IOL
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022